In patients with ILD who are started on nerandomilast on top of background nintedanib, what monitoring is most important early in therapy?

While it may seem initially that combining antifibrotics is a bad idea due to side effect profiles, it has, in fact, been done with some success. The INJOURNEY trial combined nintedanib AND perfenidone in patients with IPF, and during the study period (12 weeks), those on combined therapy lost only ...